| Literature DB >> 30380727 |
Ana Isabel Álvarez-Mercado1, Esther Bujaldon2, Jordi Gracia-Sancho3,4, Carmen Peralta5,6,7.
Abstract
Liver regeneration is a perfectly calibrated mechanism crucial to increase mass recovery of small size grafts from living donor liver transplantation, as well as in other surgical procedures including hepatic resections and liver transplantation from cadaveric donors. Regeneration involves multiple events and pathways in which several adipokines contribute to their orchestration and drive hepatocytes to proliferate. In addition, ischemia-reperfusion injury is a critical factor in hepatic resection and liver transplantation associated with liver failure or graft dysfunction post-surgery. This review aims to summarize the existing knowledge in the role of adipokines in surgical procedures requiring both liver regeneration and vascular occlusion, which increases ischemia-reperfusion injury and regenerative failure. We expose and discuss results in small-for-size liver transplantation and hepatic resections from animal studies focused on the modulation of the main adipokines associated with liver diseases and/or regeneration published in the last five years and analyze future perspectives and their applicability as potential targets to decrease ischemia-reperfusion injury and improve regeneration highlighting marginal states such as steatosis. In our view, adipokines means a promising approach to translate to the bedside to improve the recovery of patients subjected to partial hepatectomy and to increase the availability of organs for transplantation.Entities:
Keywords: adipokines; ischemic/reperfusion injury; liver regeneration; partial hepatectomy
Mesh:
Substances:
Year: 2018 PMID: 30380727 PMCID: PMC6274984 DOI: 10.3390/ijms19113395
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Prevalent action of some adipokines related to liver diseases and/or regeneration.
| Role | Name | Prevalent Described Action |
|---|---|---|
|
| Chemerin | Mediates inflammatory responses, serving as a chemo attractant to induce influx of macrophages and natural killer cells [ |
| IL-6 | Regulator of both the immune and the nervous system as well in liver regeneration [ | |
| Omentin | Inhibitor of vascular endothelial cells inflammation. Related to heart vasculature disease and insulin sensitivity [ | |
| PAI-1 | Interacts with vascular cells. It has been related with angiogenesis and pro-inflammatory cytokines. Widely associated with insulin resistance and impaired immune response [ | |
| Resistin | Involved in the pathogenesis of obesity, adipogenesis and insulin metabolism [ | |
| TGF-β | Essential in establishing immunological tolerance. Pro-inflammatory roles in inflammatory responses [ | |
| TNFα | As pro-inflammatory cytokine is involved in the development of many inflammatory diseases. “Master-regulator” of inflammatory [ | |
|
| Adiponectin | Involved in the pathogenesis of diabetes mellitus, obesity, hypertension, renal failure and atherosclerosis [ |
| Apelin | Takes part in the regulation of the physiology and pathophysiology of the circulatory system. Regulator of the metabolic balance, inflammation as well as cell proliferation and apoptosis [ | |
| Leptin | Between other functions, regulates angiogenesis, hematopoiesis, carcinogenesis, satiety, energy expenditure and the immune system [ | |
| Lipocalin | LCN2 in mainly produced by hepatocytes under acute-phase conditions. Considerable increased under stressed conditions like bacterial infection, surgical procedures or metabolic stress, plays an important role in suppressing bacterial infection by binding to bacterial catecholate-type ferric siderophores and consequent suppression of bacterial growth through the sequester of iron-laden siderophores [ | |
|
| RBP4 | Retinol transportation in the circulation [ |
| Vaspin | Potential insulin-sensitizing effects [ | |
| Vifastin | Control of energy balance and insulin sensitivity. Regulates lipid metabolism and fatty acid oxidation [ | |
|
| Angiotensinogen | It is implied in the development of liver cirrhosis, portal hypertension, angiogenesis and apoptosis [ |
| Dlk-1 | Adipogenesis, osteogenesis. Neuronal and neuroendocrine differentiation [ | |
| HB-EGF | The soluble form induces mitogenic and regenerative activities [ | |
| HGF | Proliferation, morphogenesis and anti-apoptosis [ | |
| IGF | Both prenatal and postnatal development, including cell growth, differentiation, migration, and survival [ | |
| NGF | Stimulation of growth, differentiation, survival and maintenance of neurons [ | |
| VEGF | Regulator of angiogenesis also promotes collateral vessel growth [ |
IL-6: interleukin 6; TNF-α: tumor necrosis factor alpha; LCN: lipocalin; RBP4: retinol-binding protein 4; HB-EGF: heparin-binding epidermal growth factor; VEGF: vascular endothelial growth factor; TGF-β: tumor growth factor-β; PAI-1: phosphoribosylanthranilate isomerase 1; DKL-1: delta like-1 homologue; IGF: insulin growth factor; NGF: nerve growth factor; HGF: hepatocyte growth factor.
Summarizes reported studies performed in partial hepatectomy (PH) models evaluating roles and mechanisms of adipokines in liver regeneration and damage in the last five years.
| Name | Experimental Model | Effect on Liver Function and Regeneration | Reference | ||
|---|---|---|---|---|---|
| Surgical Procedure | Specie | ||||
| PH | PartialLT | ||||
|
| 68% PH | Mouse | In NO KO mice, impairment of IL-6 induction provoked excess of hepatic lipid accumulation, increased ER stress and negatively affected hepatocyte proliferation after surgery | [ | |
| 2/3 PH | Mouse | In multidrug resistance 2 knockout (Mdr2−/−) mice, pharmacological inhibition of IL-6 signaling inhibited tumorigenesis but did not affect survival or recovery of liver mass after PH | [ | ||
| 78% PH | Mouse | A20 (an NF-κB inhibitory protein) promotes liver regeneration through enhance IL-6/STAT3 proliferative signals | [ | ||
| 70% PH+I/R 1 h warm ischemia | Mouse | Melatonin protected from hepatic damage and promoted IL-6 and TNF-α and liver regeneration | [ | ||
| 80% PH | Mouse | Melatonin-associated IL-6 increased liver microcirculation and survival | [ | ||
| 70% PH | Rat | IL-6 regulated Mcl-1L (a member of the Bcl-2 family) expression through the JAK/PI3K/Akt/CREB signaling pathway. Mcl-1 inhibited apoptosis | [ | ||
| SFSLT (30%) 1 h cold ischemia | Mouse | Melatonin activated the IL6/GP130-STAT3 pathway protecting SFS graft and promoted regeneration | [ | ||
| SFSLT (30%) 1 h cold ischemia | Rat | The administration of Gadolinium chloride (GdCl3), a Kupffer cells inhibitor inhibited IL-6/p-STAT3 signal pathway, and thus in turn increased apoptosis and suppressed liver regeneration | [ | ||
|
| 70% PH | Mouse | Knocking out PAI-1 mice was associated with a decrease in hepatocyte proliferation | [ | |
|
| 70% PH+I/R 1 h warm ischemia | Rat: Steatotic and non-steatotic livers | Steatotic livers were more resistant to the overexpression of resistin after PH under I/R. Resisting originated in liver regulated the visfatin deleterious effects on inflammation and damage | [ | |
|
| 2/3 PH | Mouse | Knockout of kupffel-like factor 10, an activator of the TGF-β/Smad signaling pathway suppressed hepatic cell proliferation | [ | |
| 70% PH | Mouse | Leucine-serine-lysine-leucine peptide promoted liver regeneration by the inhibition of TGF-β | [ | ||
|
| 2/3 PH | Mouse | BMP-9 (a member of the TGF-β family) disturbed the proliferative response and promoted fibrosis | [ | |
| SFSLT (50%) 55–65 min cold ischemia | Rat | Administration of autologous adipose-derived mesenchymal stem cells increased IL-10 and TGF-β avoiding acute rejection and decreasing inflammatory responses | [ | ||
|
| 2/3 PH | Mouse | Hepatocyte expression of ADAM17 (a major regulator of TNF, TNFR1, and AR amphiregulin) was not essential for hepatocyte proliferation in ADAM17 KO mice | [ | |
| 2/3 PH | Mouse | TNF-α injection exacerbates the regenerative failure in Gclm−/− mice | [ | ||
| SFSLT (50%) 10 min or 10 h cold | Rat | TNFα expression was affected in a different way depending of the time of cold ischemia | [ | ||
|
| 2/3 PH | Mouse | Adiponectin regulated regeneration controlling cell cycle progression, cytokine signaling and growth factor bioavailability | [ | |
|
| 70% PH | Mouse | The blockade of the apelin-APJ system pharmacologically by F13A promoted cell-cycle progression and liver regeneration | [ | |
|
| 70% PH | Rat | Leptin administration increased regeneration, liver weight and reduced damage | [ | |
|
| 2/3 PH | Mouse | LCN2 was induced in mice after PH although increased expression of LCN2 had no effects in hepatocyte proliferation | [ | |
| 2/3 PH | Mouse | In LCN2Hep−/− after treatment with IL-6, hepatocyte-derived LCN2 promoted liver regeneration | [ | ||
| Major PH+I/R 20 min warm ischemia | Mouse: Steatotic and non-steatotic livers | Using wild type and mice over expressing LCN2, it was observed that LCN2 had deleterious effects in steatotic livers | [ | ||
| 70% or 40% PH | Rat | Expression of the LCN2 mRNA was higher in 70% than in 40% PH | [ | ||
|
| SFSLT (55–70%). 40 min cold ischemia | Rat: Steatotic and non-steatotic livers | LCN2 is upregulated in steatotic small liver grafts. LCN2 exacerbated graft injury and promoted macrophage infiltration | [ | |
|
| 70% PH 1 h warm ischemia | Rat: Steatotic and non-steatotic livers | Visfatin administration impaired damage and regenerative response in steatotic livers | [ | |
|
| 70% PH | Mouse: Colorectal cancer liver metastases induction | Captopril (an inhibitor of renin–angiotensin system) did not impair liver regeneration Captopril exerted its effects on established tumors at only late stage acting as an angiogenic inhibitor, reducing widely tumor vessel density and enhancing tumor cell apoptosis | [ | |
| 70% PH | Mouse | Captopril enhanced early liver regeneration, effect associated with increased hepatic stem cells and MMP-9 protein | [ | ||
|
| 2/3 PH | Mouse | Using focal adhesion kinase (FAK) KO mice, the authors show that Fakdeficiency enhanced liver regeneration modulating TNFα/HB-EGF axis | [ | |
|
| 70% PH | Rat | Low-power laser irradiation enhanced the HGF/Met axis and Akt and Erk pathways improving liver regeneration | [ | |
|
| 70% PH | Mouse | IGF-2 induced hepatocyte proliferation | [ | |
|
| 68% PH | Mouse | Hif2a-Vegf axed as a prime regulator of regenerative sinusoidal endothelial cells-hepatocyte crosstalk and revealed a crucial role for oxygen during liver regeneration | [ | |
| 90% PH | Rat: Steatotic and non-steatotic livers | Treatment with VEGF improved survival and stimulated liver regeneration | [ | ||
|
| 90% PH | Rat | VEGF-sdf1 pathway in the liver is upregulated after PH, and this increases bone marrow production of progenitors of sinusoidal endothelial cells, which are required for liver regeneration | [ | |
| 70% PH | Rat | The over-expression of VEGF following surgery promoted angiogenesis | [ | ||
| 70% PH | Rat | After transplant stem cells and MSCs transfected with VEGF, an increment in proliferation of hepatocytes was observed. VEGF transected MSCs also promoted the secretion of several growth factors as HGF and PDGF. These effects supported liver function and regeneration | [ | ||
| 70% PH | Rat | In rats exposed to chemotherapy, the treatment with Bevacizumab (Anti-VEGF-A) did not affect liver cells proliferation after surgery | [ | ||
| SFSLT (50%) 55–65 min. cold ischemia | Rat | The over-expression of VEGF induced hepatocyte proliferation and neovascularization of the remnant liver | [ | ||
Ang: angiotensin; PH: partial hepatectomy; MM9-protein: Matrix metallopeptidase 9; min: minutes; I/R: ischemic reperfusion; HGF: hepatocyte growth factor; Akt: Protein kinase B; ErK: extracellular signal-regulated kinase; PH: partial hepatectomy; lipocalin: LCN; mRNA: messenger ribonucleic acid; VEGF: vascular endothelial growth factor; MSCs: mesenquimal stem cells; TGF-β: tumor growth factor-β; PDGF: platelet-derived growth factor; HB-EGF: heparin binding epidermal growth factor; FGF: fibroblast growth factor; BMP-9: bone morphogenetic protein 9; NO: nitric oxide; SFSLT: small-for-size liver transplantation; IL-6: interleukin 6; MCL-1: myeloid cell leukemia1; Bcl-2: B-cell lymphoma 2; JAK: JAK kinase; CREB: cAMP response-element-binding; PAI-1: phosphoribosylanthranilate isomerase 1; TNF-α: tumor necrosis factor alpha; Gclm: glutamate-cysteine ligase.
Future perspectives in the use of adipokines implied in regeneration and/or liver diseases as therapeutic target to alleviate I/R injury and improve liver regeneration in the surgery of hepatic resections and partial liver transplantation.
| Studies Reported in the Last Five Years | |||
|---|---|---|---|
| Name | PH | Partial LT | Future Perspectives |
|
| 6 | 2 | Studies performed using different % of PH. IL-6 could be a potential target to promote hepatocyte proliferation and decrease damage. However we must to be cautious because the controversial results in the presence of tumorigenesis and the fact that any of the authors evaluated its effect in PH under I/R |
|
| 1 | 0 | Only one reported study in an experimental mouse model of PH. PAI-1 was associated with a decrease in hepatocyte proliferation. More studies in the setting of PH under I/R, partial LT as well as considering steatotic status are required |
|
| 1 | 0 | Its role in partial liver transplantation from steatotic and non-steatotic grafts has not been described. Further studies are required to consider its relevance |
|
| 3 | 1 | Deleterious effect in the hepatic proliferative response |
|
| 2 | 1 | Although implied in hepatocyte proliferation, controversial results have been reported. Further studies are necessaries to elucidate the precise role of TNF-α in regeneration in surgical procedures as well as in the presence of steatosis |
|
| 1 | 0 | As in the previous case, not many studies have been recently reported results and its modulation could beneficiate specially the outcome of hepatic resection in steatotic livers |
|
| 1 | 0 | Only one study published make mandatory more research focused in this adipokine |
|
| 1 | 0 | Not many works have been reported in the setting of PH, PH+I/R or partial LT. Since leptin deficiency impaired liver regeneration in obese mice, drugs aimed to modulate this adipokine would improve prognosis in liver transplantation from steatotic donors |
|
| 4 | 1 | Controversial results even using the same experimental model of surgery. More studies are necessaries |
|
| 1 | 0 | Only one study published make mandatory more research focused in this adipokine |
|
| 2 | 0 | Promising results for cancer patients subjected to hepatic resection although more studies are necessaries |
|
| 1 | 0 | Only one study published make mandatory more research focused in this adipokine |
|
| 1 | 0 | Only one study published make mandatory more research focused in this adipokine |
|
| 1 | 0 | Only one study published make mandatory more research focused in this adipokine |
|
| 6 | 1 | Wide consensus in the published results even when different surgical procedures are compared. The benefits of VEGF for liver function and proliferation point that its pharmacological modulation would improve prognosis after surgery |
LT: liver transplantation; Ang: angiotensin; I/R: ischemic reperfusion; HGF: hepatocyte growth factor; PH: partial hepatectomy; lipocalin: LCN; VEGF: vascular endothelial growth factor; TGF-β: tumor growth factor-β; HB-EGF: heparin binding epidermal growth factor; FGF: fibroblast growth factor; IL-6: interleukin 6; PAI-1: phosphoribosylanthranilate isomerase 1; TNF-α: tumor necrosis factor alpha; IGF: insulin growth factor.
Figure 1Schematic representation of the currently explored adipokines reported as involved in regeneration and/or liver injury in surgical procedures requiring liver regeneration and vascular occlusion in the last five years. Pink: adipokines in non-steatotic liver surgery. Blue: adipokines in steatotic liver surgery. The symbol ? means that controversial results have been reported. ↑ Promotion or activation of the process. ┤ Inhibition or decrease of the process. PH: partial hepatectomy; I/R: ischemic reperfusion; SFSLT: liver resection and small-for-size liver transplantation; HGF: hepatocyte growth factor; VEGF: vascular endothelial growth factor; TGF-β: tumor growth factor-β; HB-EGF: heparin binding: epidermal growth factor; PAI-1: phosphoribosylanthranilate isomerase 1; IL-6: interleukin 6; TNF-α: tumor necrosis factor; Ang: angiotensin; HB-EGF: heparin binding epidermal growth factor; NAD nicotinamide adenine dinucleotide; IGF: insulin growth factor; HIF-2 α: hypoxia-inducible factor alpha.